Avantax Planning Partners Inc. Increases Stake in ABVC BioPharma, Inc. (NASDAQ:ABVC)

Avantax Planning Partners Inc. increased its position in shares of ABVC BioPharma, Inc. (NASDAQ:ABVC) by 269.1% during the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm owned 143,968 shares of the company’s stock after buying an additional 104,968 shares during the period. Avantax Planning Partners Inc. owned about 1.11% of ABVC BioPharma worth $85,000 at the end of the most recent quarter.

ABVC BioPharma Price Performance

ABVC opened at $0.70 on Thursday. The business’s 50-day moving average is $0.57 and its two-hundred day moving average is $0.58. ABVC BioPharma, Inc. has a 1 year low of $0.40 and a 1 year high of $1.73. The firm has a market capitalization of $9.03 million, a PE ratio of -0.81 and a beta of 0.67.

About ABVC BioPharma

ABVC BioPharma, Inc, a clinical stage biopharmaceutical company, develops drugs and medical devices to fulfill unmet medical needs in the United States. The company is developing ABV-1501, which is in Phase II clinical trials a combination therapy for triple negative breast cancer; ABV-1504 has completed Phase II clinical trials for major depressive disorders; ABV-1505, which is in Phase II clinical trials for adult attention deficit hyperactivity disorder; ABV-1703, which is in Phase II clinical trials for the treatment of metastatic pancreatic cancer; ABV-1702, which is in Phase II clinical trials to treat myelodysplastic syndromes; and ABV-1601 that is in Phase I/II clinical trials for treating depression in cancer patients.